Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

Summary

The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP) and fundus autofluorescence (FAF) in patients with neovascular age-related macular degeneration receiving combination of ranibizumab (LucentisTM) and verteporfin (Visudyne®) therapy

Timeline

Start

2006-08

Primary completion

2008-02

Completion

—

Drugs

Indications